Samsung Biologics Co Ltd (207940) fair value: what the stock is really worth
As of Nov 5, 2026: fair value (intrinsic value) of Samsung Biologics Co Ltd stock KRW 1,644,500, price KRW 1,520,000, upside +8.2%, quality 82 out of 100. Rating: fairly valued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range 1,000,786 KRW – 1,965,000 KRW · fair‑value band 947,964 KRW – 2,140,710 KRW · the 1,520,000 KRW price screens below the 1,644,500 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Samsung Biologics Co in your weekly email
Every Wednesday you see whether Samsung Biologics Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally.
Show moreShow less
Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing.
The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, and regulatory support services; and quality services and analytical testing services, such as IPC and release testing, stability study and testing, environmental monitoring, biosafety testing, as well as manufactures drug substance.
In addition, it engages in the development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.
Stock analysis
Samsung Biologics Co Ltd (207940) currently trades at 1,520,000 KRW, while our model-based Fair Value estimate is 1,644,500 KRW, so the stock looks roughly fairly valued today (gap 7.6%).
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 1,780,770 KRW per share, and 2 of the 24 models we run sit above the 1,520,000 KRW price.
Bear case: the Economic Profit group reads lowest at 374,632 KRW, and 22 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 947,964 KRW (bear) to 2,140,710 KRW (bull), the price of 1,520,000 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 82/100 (high quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Samsung Biologics Co Ltd reported revenue of 4.6T KRW in FY2025 versus 1.6T KRW in FY2021, a compound +30.6%/yr. Reported net income was 1.8T KRW in FY2025, compounding +45.9%/yr from FY2021.
Key figures
Market cap 70.4T KRW (≈ $51.8B) Large · P/E ratio 37.5 · P/S ratio 13.7 · EPS (TTM) 39,725 KRW · Net margin 38.8% · Return on equity 18.5% · Return on assets (EBIT) 9.2% · Operating margin 44.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 84 out of 100 (low confidence).
What moves the price
The share trades about 23% below its 52-week high and 29% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 8%, 207940 screens richer than that median.
Fair Value models
Bear947,964 KRWFair Value 1,644,500 KRWBull2,140,710 KRW
Price 1,520,000 KRW · Upside +8.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (33,630 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+30.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+31.4%
Start year 2020 (pandemic). Over 10 years: +47.9% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+40.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+50.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+50.9%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.25% → 45%
2025 sits 220% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+34.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+14.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +32.0% a year for the price and +12.4% for the forecasts.
AI conclusion: Samsung Biologics advances peptide capabilities via the PolyPeptide acquisition for obesity and diabetes demand, yet prolonged labor disputes undermine operational stability in its core CDMO business.
Main risk: Ongoing union strikes and negotiations at its main Songdo site could interrupt continuous biologics production processes, erode client confidence in supply chain stability and constrain new orders or expansion plans such as the PolyPeptide acquisition.
Bull case: Successful resolution of labor talks combined with the PolyPeptide acquisition could strengthen peptide capabilities and restore client trust, enabling faster capacity utilization and differentiation in obesity and diabetes treatments.
Bear case: Persistent labor tensions could lead clients to shift contracts to more stable rivals like Lonza, delaying expansions and limiting the company's ability to capitalize on demand growth in complex biologics and peptides.
Samsung Biologics is advancing its peptide capabilities through the PolyPeptide acquisition, targeting fast-growing demand in obesity and diabetes treatments. At the same time, a prolonged labor dispute continues to test operational stability in its core CDMO business, where clients prioritize reliable supply chains. Will management and the union reach an agreement that preserves customer confidence, or will the tensions constrain the company's ability to execute on its expansion plans?
Compare Samsung Biologics Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 559 stocks
Beats the industry median on 7/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score82 · Top 25%
Fair Value upside+8.2% · Top 25%
Profitability
Return on equity (12 months)18.5% · Top 25%
Return on assets16.1% · Top 25%
Net margin (12 months)38.8% · Top 25%
Operating margin (12 months)44.4% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)30.2% · Top 25%
Balance sheet
Debt / equity0.08× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Samsung Biologics Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/207940
Frequently asked questions
Is Samsung Biologics Co Ltd (207940) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of 1,644,500 KRW versus a price of 1,520,000 KRW, about +8% upside (fairly valued).
What is the fair value of 207940?
Our model-based fair value for Samsung Biologics Co Ltd is 1,644,500 KRW (as of Nov 5, 2026), built from audited fundamentals. The current price: 1,520,000 KRW.
What is the quality score of 207940?
Samsung Biologics Co Ltd has a Quality Score of 82/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Samsung Biologics Co Ltd (207940)?
Our model-based price target is the fair value of 1,644,500 KRW (as of Nov 5, 2026) from 24 valuation models. Cautious scenario 947,964 KRW, optimistic scenario 2,140,710 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Samsung Biologics Co Ltd stock forecast for 2026?
Our models put fair value at 1,644,500 KRW, about +8% upside versus a price of 1,520,000 KRW (fairly valued). Cautious scenario 947,964 KRW, optimistic scenario 2,140,710 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Samsung Biologics Co Ltd (207940)?
Samsung Biologics Co Ltd reported trailing-twelve-month revenue of about 5.1T KRW (latest available figure, as of Nov 5, 2026).
What growth is priced into Samsung Biologics Co Ltd (207940)?
For today's price to be fair in a discounted-cash-flow model, Samsung Biologics Co Ltd would have to grow free cash flow by +34.8 % per year for five years (discount rate 8.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +31.4 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of 207940 use?
Our models discount Samsung Biologics Co Ltd at 8.4 %: a base by market capitalisation (large), damped by beta 0.15, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Samsung Biologics Co Ltd that is +34.8 % per year a year over ten years, using the same discount rate (8.4 %) and the same formula as our fair value.
How much growth has Samsung Biologics Co Ltd (207940) delivered so far?
Over the past 5 years revenue at Samsung Biologics Co Ltd grew +31.4 % a year. The price currently implies +34.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Samsung Biologics Co Ltd (207940) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Samsung Biologics Co Ltd (+34.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Samsung Biologics Co Ltd (207940)?
The free-cash-flow yield on the price is 1.10 %: that much free cash flow Samsung Biologics Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (8.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Samsung Biologics Co Ltd (207940)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Samsung Biologics Co Ltd it is 1,644,500 KRW per share (as of Nov 5, 2026), against a price of 1,520,000 KRW. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Samsung Biologics Co Ltd stock overvalued or undervalued in 2026?
As of Nov 5, 2026, 207940 trades below its calculated fair value: price 1,520,000 KRW, fair value 1,644,500 KRW, a gap of about +8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 207940?
No. The price is what the market pays today (1,520,000 KRW); the fair value is what the company's own numbers justify (1,644,500 KRW). For Samsung Biologics Co Ltd the two are 124,500 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Samsung Biologics Co Ltd worth?
The market values Samsung Biologics Co Ltd at about 70.4T KRW (market capitalisation, as of Nov 5, 2026). Per share that is 1,520,000 KRW; our models calculate a fair value of 1,644,500 KRW per share.
What do the bullish and bearish scenarios say about 207940?
Our models span a range for Samsung Biologics Co Ltd: cautious scenario 947,964 KRW, base 1,644,500 KRW, optimistic 2,140,710 KRW per share (as of Nov 5, 2026, price 1,520,000 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 207940?
Samsung Biologics Co Ltd trades at a price-to-earnings ratio of 37.5 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 1,644,500 KRW is built from several models across several years. Other multiples: PEG 1.8, P/B 9.4, P/S 13.7, EV/EBITDA 25.0.
What is the PEG ratio of 207940?
The PEG ratio of Samsung Biologics Co Ltd is 1.83 (P/E divided by earnings growth, as of Nov 5, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Samsung Biologics Co Ltd (207940)?
Balance-sheet figures for Samsung Biologics Co Ltd (as of Nov 5, 2026): return on equity 18.5%, debt of 0.08 per unit of equity. They feed the Quality Score of 82/100, which measures business quality independently of the share price.
How far is 207940 from its 52-week high?
Samsung Biologics Co Ltd trades at 1,520,000 KRW, about 23% below its 52-week high of 1,965,000 KRW and 29% above the low of 1,182,000 KRW (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of 1,644,500 KRW is for.
Which stocks are comparable to Samsung Biologics Co Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, BeOne Medicines AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Samsung Biologics Co Ltd stock attractive at the current price?
The data as of Nov 5, 2026: price 1,520,000 KRW, calculated fair value 1,644,500 KRW (+8%), Quality Score 82/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 207940 calculated?
We run Samsung Biologics Co Ltd through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1,644,500 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. Samsung Biologics Co Ltd currently trades 8% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Samsung Biologics Co Ltd (207940)?
The closing price on Nov 5, 2026 was 1,520,000 KRW. Our model-based fair value is 1,644,500 KRW, about +8% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Samsung Biologics Co Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (947,964 KRW to 2,140,710 KRW) leaves room in how you read the outcome.
Key figures of Samsung Biologics Co Ltd
How large is the market capitalisation of Samsung Biologics Co Ltd (207940)?
The market capitalisation of Samsung Biologics Co Ltd is 70.4T KRW (≈ $51.8B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Samsung Biologics Co Ltd (207940)?
The price-to-sales ratio of Samsung Biologics Co Ltd is 13.7 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Samsung Biologics Co Ltd (207940)?
Earnings per share at Samsung Biologics Co Ltd are 39,725 KRW (price ÷ EPS = P/E 37.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Samsung Biologics Co Ltd (207940)?
The net margin of Samsung Biologics Co Ltd is 38.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Samsung Biologics Co Ltd (207940)?
The return on equity (ROE) of Samsung Biologics Co Ltd is 18.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Samsung Biologics Co Ltd (207940)?
On an EBIT basis the return on assets of Samsung Biologics Co Ltd is 9.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Samsung Biologics Co Ltd (207940)?
The operating margin of Samsung Biologics Co Ltd is 44.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Samsung Biologics Co Ltd (207940)?
Revenue at Samsung Biologics Co Ltd is growing +30.2% versus a year earlier (3y avg +14.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Samsung Biologics Co Ltd (207940)?
Earnings per share at Samsung Biologics Co Ltd are growing +32.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Samsung Biologics Co Ltd (207940) carry?
The net debt of Samsung Biologics Co Ltd is 770B KRW (fiscal year 2025, ≈ 1.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Samsung Biologics Co Ltd in the live analysis
One click puts Samsung Biologics Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 5, 2026